Login to Your Account

Clinic Roundup

Thursday, July 7, 2011
CytRx Corp., of Los Angeles, reported that its tumor-targeted doxorubicin conjugate, INNO-206, has delivered doxorubicin safely at doses more than four times higher than the standard doxorubicin dose in its open-label Phase Ib trial. All eight patients treated in the study to date were diagnosed with advanced soft-tissue sarcomas. A total of 24 patients with advanced solid tumors who have failed standard therapies will be enrolled in the ongoing trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription